ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Donor-derived Cell-free Dna In Donor Specific Antibody Positive Kidney Transplant Recipients

D. Cheng1, X. Li2, T. Jiang2, H. Liu2, Y. Zhou3, H. Shi3

1National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China, 2Research and Development, AlloDx Biotech Co.Ltd., Suzhou, China, 3Precise Medicine Center, Biology and Science School, JiangSu University, Zhenjiang, China

Meeting: 2019 American Transplant Congress

Abstract number: A24

Keywords: Genomic markers, Kidney transplantation, Medicare, Rejection

Session Information

Session Name: Poster Session A: Acute Rejection

Session Type: Poster Session

Date: Saturday, June 1, 2019

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker of kidney allograft injury. Studies examining the clinical validity of this biomarker have identified cut off values for kidney allograft rejection: <1% of dd-cfDNA level reflect the absence of active rejection (T cell-mediated type >IA or ABMR) and >1% indicate a probability of active rejection. This study assessed the relationship between dd-cfDNA and clinic events (Creatinine, DSA, Renal allograft IgAN and Albuminuria)

*Methods: Donor-derived cell-free DNA was assayed in 30 plasm samples with two reasons: high serum creatinine (13 samples) or DSA positive (17 samples). Dd-cfDNA quantification through Target Region Capture Sequencing and calculated by Maximum Likehood Estimation (MLE). Samples with detection value greater than 1% or suspicion of kidney injury were determined for graft biopsy.

*Results: The mean level of quantification of ddcfDNA in 30 plasm is 1.24% ± 1.4%. 17 patients have positive DSA, but only 8 patients (47%) dd-cfDNA higher than 1%, allograft biopsy performance in 15 patients confirmed all of 8 patients (higher dd-cfDNA) show pathologically rejection: 4 patients (1.3%, 1.68%, 1.9% and 2.52%) have chronic active humoral rejection, 3 patients (2.08%, 4.04% and 5.71%) belong to AMR. But none of allograft rejection evidence in remain 7 patients. The positive predictive value for DSA positive was 47%. 22 patients (73%) detected dd-cfDNA lower than 1%. Among them, 15 patients clinically performed pathological biopsy: 1 patient (0.67%) pathologically show chronic active rejection, 5 patients (0.33%, 0.54%, 0.54%, 0.69% and 0.76%) show allograft IgAN but 2 patients show DSA positive, The remain 9 patients (0.59% ± 0.1%) show toxicity of CNI or board line change. The positive predictive value for dd-cfDNA (level >1%) was 88%.

*Conclusions: Compared with DSA, dd-cfDNA can predict rejection more accurately. Detection of dd-cfDNA maybe service as a pre-biopsy necessity assessment in kidney transplant recipients

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cheng D, Li X, Jiang T, Liu H, Zhou Y, Shi H. Donor-derived Cell-free Dna In Donor Specific Antibody Positive Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/donor-derived-cell-free-dna-in-donor-specific-antibody-positive-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences